After 10 months of supply chain delays, Universal Biosensors, Inc.’s (ASX:UBI) first Xprecia Prime devices were delivered in Europe.
Almost immediately following receipt, UBI made its first sales of Xprecia Prime devices to customers.
This is a significant achievement for UBI and something we have been anticipating for many months. It represents the beginning of our new coagulation business based around our next generation Xprecia Prime platform,” CEO John Sharman said.
“The sales performance for our coagulation business was extremely frustrating throughout 2022. Even though Xprecia Prime was cleared for sale by European regulators in February 2022, supply chain issues meant that we could not get any stock delivered into Europe until now.
“When we add the negative impact on sales of the unwinding of the Siemens Healthineers relationship (which continues to sell down its existing stockholding to meet market demand), sales for 2022 are low.
“Looking forward, the Siemens relationship ends in March, our own distribution network is growing and our new Xprecia Prime device looks very promising in terms of sales. The supply chain issues appear behind us, our USA based clinical trial is complete and we are well positioned to submit our 510K application to have Xprecia Prime approved for sale in the USA. We are looking forward to a much better sales performance from our coagulation business during 2023.”
